Showing results (281-290 of 301) with videos related to
Sort By:
Pageof 31
Cancer|May 31, 2017
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J Ocean, Alexander N Starodub, Aditya Bardia, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2014
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinomaPierre-Yves Salaun, Loïc Campion, Catherine Ansquer, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2010
Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806Fook T Lee, Graeme J O'Keefe, Hui K Gan, et al.Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2018
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY TrialsJacques-Eric Gottenberg, Thomas Dörner, Hendrika Bootsma, et al.NPJ Breast Cancer|August 29, 2022
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancerHope S Rugo, Sara M Tolaney, Delphine Loirat, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal CancerEfrat Dotan, Steven J Cohen, Alexander N Starodub, et al.Blood|January 14, 2011
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphomaLapo Alinari, Bo Yu, Beth A Christian, et al.Blood|November 2, 2011
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell deathLapo Alinari, Emilia Mahoney, John Patton, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 9, 2003
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?Robert M Sharkey, Arnold Brenner, Jack Burton, et al.Pageof 31